Summit Therapeutics Shares Drop Following FDA Rejection of Ivonescimab Combination Therapy

Summit Therapeutics (SMMT) saw its stock plunge approximately 20% following an FDA rejection of its combination therapy, Ivonescimab plus chemotherapy, for advanced EGFR-mutated non-small cell lung cancer. While the Harmoni trial indicated a delay in disease progression or death, the FDA determined it failed to demonstrate a statistically significant survival benefit required for approval. The rejection has increased investor anxiety regarding Capricor Therapeutics (CAPR), which faces its own critical FDA decision on November 22 for Deramiocel. Capricor is seeking approval for treating upper limb impairment in Duchenne muscular dystrophy patients, following previous regulatory setbacks and a negative advisory panel vote regarding heart disease applications.

4 articles from 4 sources · updated

Coverage